Why Abbott Laboratories (ABT) Stock Is Falling Today

Recent Developments at Abbott Laboratories

Abbott Laboratories (NYSE:ABT), a leading provider of healthcare products and medical devices, experienced an 8.3% decline in its share price during the afternoon trading session. This drop followed the release of its fourth-quarter financial results, which fell short of analysts’ revenue projections.

Although the company reported a 4.4% year-over-year increase in sales, reaching $11.46 billion, this figure was below the anticipated $11.8 billion. Organic revenue, which excludes the impact of one-time items such as currency changes, grew by 3% compared to the previous year—also missing expectations. Adjusted earnings per share came in at $1.50, matching forecasts, but the revenue miss appeared to unsettle investors. On a brighter note, Abbott improved its operating margin to 19.6%, up from 17.4% in the same period last year, reflecting greater operational efficiency. However, the company’s projected earnings for 2026—$5.68 per share at the midpoint—met analyst estimates but did little to ease concerns about the revenue shortfall.

Market reactions can sometimes be exaggerated, and significant price drops may create attractive entry points for long-term investors. Considering this, could now be a good opportunity to invest in Abbott Laboratories?

How the Market Is Responding

Abbott’s stock has generally shown low volatility, with only two instances in the past year where the price moved more than 5% in a single session. Today’s sharp decline suggests that investors view the latest news as significant, though it may not fundamentally alter the overall outlook for the company.

Six months ago, we observed the largest move of the past year when Abbott’s shares fell 8.1%. This occurred after the company posted second-quarter results that exceeded analyst expectations but chose to maintain its full-year guidance, which may have disappointed those hoping for a more optimistic forecast.

In that quarter, Abbott reported adjusted earnings per share of $1.26 and revenue of $11.14 billion, both surpassing Wall Street’s estimates of $1.25 EPS and $11.07 billion in revenue. The Medical Devices division performed especially well, growing 13.4% year-over-year, fueled by strong demand for Diabetes Care products like FreeStyle Libre. Despite this robust performance—including a 7.5% organic sales increase in its core business—the company kept its 2025 earnings outlook unchanged, projecting adjusted diluted EPS between $5.10 and $5.20. The lack of an upward revision, despite strong results, likely contributed to the negative market reaction as investors had hoped for a more bullish forecast.

Stock Performance and Investment Perspective

Since the start of the year, Abbott Laboratories’ stock has declined by 11%. Currently trading at $110.50 per share, the stock sits 21.2% below its 52-week high of $140.22, reached in March 2025. An investor who purchased $1,000 worth of Abbott shares five years ago would now have an investment valued at $979.23.

Many major companies—such as Microsoft, Alphabet, Coca-Cola, and Monster Beverage—began as lesser-known growth stories that capitalized on major trends. We believe the next big opportunity lies in a profitable AI semiconductor company that has yet to catch Wall Street’s full attention.